Inspire Medical Systems Faces Class Action Over Failed Product Launch
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Source: PRnewswire
- Product Launch Failure: The launch of Inspire V is alleged to be a disaster due to poor demand and excess inventory among providers, leading to the company's failure to complete essential customer training and IT system setups, which negatively impacted market acceptance.
- Investor Confidence Eroded: Despite the company's claims of having taken necessary steps for a successful launch, it failed to meet basic requirements, significantly diminishing investor confidence in the company's future prospects.
- Increased Legal Risks: Inspire faces legal action for failing to ensure Medicare reimbursement and update claims processing software, which could result in substantial damages and reputational harm, further affecting stock prices.
- Shareholder Action Call: Shareholders are encouraged to register for the class action by January 5, 2026, to seek compensation for losses incurred due to misleading statements, highlighting investor concerns regarding corporate governance.
INSP
$96.54+Infinity%1D
Analyst Views on INSP
Wall Street analysts forecast INSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INSP is 115.58 USD with a low forecast of 82.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 95.270
Low
82.00
Averages
115.58
High
180.00
Current: 95.270
Low
82.00
Averages
115.58
High
180.00
About INSP
Inspire Medical Systems, Inc. is a medical technology company. The Company is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. It has developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
